


Supplemental Figure 1: Flow-chart of the trial. The randomization was made by a randomization plan generator in blocks of six patients (Helsinki University Central Hospital Pharmacy). The allocation sequence was produced independently and concealed until a patient had finished the trial. The trial was double-blind. The study protocol was approved by the ethical committees of Helsinki University Hospital and Helsinki Deaconess Institute and by the National Agency of Medicines (no 64/2003).



Supplemental Figure 2: The fluctuation in the proportion of amphetamine-positive urine samples during the 20-week treatment period. The horizontal axis indicates the weeks of trial, the vertical axis the values of fluctuation process, and the red lines the level of significant change ($p < 0.05$) from baseline. A statistically significant reduction in the proportion of amphetamine-positive urine samples is seen in the methylphenidate arm after 18 weeks. M= methylphenidate, A= aripiprazole and P= placebo.

